Sugi Predict

Sugi Predict / Compounds / SCHEMBL18622975

SCHEMBL18622975

SCHEMBL18622975

Cc1cc(-c2ccco2)n(-c2ccc3cc(Br)ccc3c2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ KDM4E B2RXH2 2/20 0.64
▸ HPGD P15428 1/20 0.64
▸ HSD17B10 Q99714 1/20 0.64
▸ TDP1 Q9NUW8 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ PIK3R1 P27986 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PTGS2 P35354 3/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ P2RY6 Q15077 1/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.38
▸ F10 P00742 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18622983 0.85 KDM4E (0.64) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL29825485 0.82 PTGS2 (0.46) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL17064703 0.82 PTGS2 (0.46) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL12528294 0.78 KDM4E (1.00) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18622977 0.78 KDM4E (0.72) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18622990 0.78 ALDH1A1 (0.76) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18623253 0.76 ALDH1A1 (0.58) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL16660102 0.76 MAPT (0.58) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14062757 0.72 ALDH1A1 (0.67) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18623216 0.72 ALDH1A1 (0.60) MAPTALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708332-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11685721-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-06-27 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708332-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 MAPT 3007/4885ALDH1A1 1220/4885KDM4E 1055/4885
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 MAPT 2830/4885ALDH1A1 1065/4885KDM4E 1757/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 MAPT 2685/4885ALDH1A1 1425/4885KDM4E 1688/4885
US-11685721-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 MAPT 2984/4885ALDH1A1 1136/4885KDM4E 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.